Download PDF
Semin Neurol 2022; 42(04): 494-502
DOI: 10.1055/s-0042-1757926
Review Article

Acute Treatment of Headache (Focus on Migraine)

Chia-Chun Chiang
1   Department of Neurology, Mayo Clinic, Rochester, Minnesota
,
Rashmi B. Halker Singh
2   Department of Neurology, Mayo Clinic, Scottsdale, Arizona
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Acute treatments for migraine and cluster headache are necessary to abort attacks, relieve pain and associated symptoms, and restore an individual's ability to function. Acute headache treatments consist of a variety of medication and nonmedication options. In this article, we discuss the approach to acute treatment of migraine and cluster headache. We summarize the level of evidence to support each acute medication class according to recent systematic reviews and meta-analyses, as well as guideline recommendations from the American Headache Society, American Academy of Neurology, and European Federation of Neurological Society.

Keywords

migraine - cluster headache - acute treatment - triptans - calcitonin gene-related peptide


Publication History

Article published online:
02 November 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Stovner LJ, Nichols E, Steiner TJ. et al; GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17 (11) 954-976
    CrossrefPubMedGoogle Scholar
  • 2 Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache 2018; 58 (Suppl. 01) 4-16
    CrossrefPubMedGoogle Scholar
  • 3 Chiang C-C, Starling AJ, Buras MR, Golafshar MA, VanderPluym JH. A pilot exploratory study comparing the King-Devick test (KDT) during and between migraine attacks. Cephalalgia 2020; 40 (03) 307-312
    CrossrefPubMedGoogle Scholar
  • 4 Ailani J, Burch RC, Robbins MS. Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 2021; 61 (07) 1021-1039
    CrossrefPubMedGoogle Scholar
  • 5 International Headache Society. Headache Classification Committee of the IHS. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1-211
    Google Scholar
  • 6 Joshi S, Rizzoli P, Loder E. The comorbidity burden of patients with cluster headache: a population-based study. J Headache Pain 2017; 18 (01) 76
    CrossrefPubMedGoogle Scholar
  • 7 Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine. Headache 2016; 56 (07) 1194-1200
    CrossrefPubMedGoogle Scholar
  • 8 Diamond M, Cady R. Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. Am J Med 2005; 118 (Suppl. 01) 18S-27S
    PubMedGoogle Scholar
  • 9 Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015; 55 (01) 3-20
    CrossrefPubMedGoogle Scholar
  • 10 Chiang C-C, Schwedt TJ. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine - the monoclonal antibodies and gepants. Prog Brain Res 2020; 255: 143-170
    CrossrefPubMedGoogle Scholar
  • 11 Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB. COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 2018; 91 (24) e2222-e2232
    CrossrefPubMedGoogle Scholar
  • 12 VanderPluym JH, Halker Singh RB, Urtecho M. et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA 2021; 325 (23) 2357-2369
    CrossrefPubMedGoogle Scholar
  • 13 Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55 (06) 754-762
    CrossrefPubMedGoogle Scholar
  • 14 Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine?. Pain 2005; 115 (1-2): 1-4
    CrossrefPubMedGoogle Scholar
  • 15 Ashcroft DM, Millson D. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 2004; 13 (02) 73-82
    CrossrefPubMedGoogle Scholar
  • 16 Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev 2014; CD008616 (05) CD008616
    PubMedGoogle Scholar
  • 17 Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia 2001; 21 (02) 129-136
    CrossrefPubMedGoogle Scholar
  • 18 Poolsup N, Leelasangaluk V, Jittangtrong J, Rithlamlert C, Ratanapantamanee N, Khanthong M. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005; 30 (06) 521-532
    CrossrefPubMedGoogle Scholar
  • 19 Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache 2007; 47 (08) 1169-1177
    CrossrefPubMedGoogle Scholar
  • 20 Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; CD008615 (02) CD008615
    PubMedGoogle Scholar
  • 21 Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; CD009665 (02) CD009665
    PubMedGoogle Scholar
  • 22 Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev 2016; 4: CD008541
    PubMedGoogle Scholar
  • 23 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1337-1345
    CrossrefPubMedGoogle Scholar
  • 24 Cameron C, Kelly S, Hsieh SC. et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 2015; 55 (Suppl. 04) 221-235
    CrossrefPubMedGoogle Scholar
  • 25 Park GRT. 27709 N. Imitrex Tablets Sumatriptan succinate NDA 020132/S-028 [package insert] n.d.
    PubMed
  • 26 Pharmaceuticals DS. Inc. D.H.E. 45® [package insert] (dihydroergotamine mesylate) Injection, USP n.d.
    PubMed
  • 27 Lipton RB, Dodick DW, Ailani J. et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 2019; 322 (19) 1887-1898
    CrossrefPubMedGoogle Scholar
  • 28 Dodick DW, Lipton RB, Ailani J. et al. Ubrogepant for the treatment of migraine. N Engl J Med 2019; 381 (23) 2230-2241
    CrossrefPubMedGoogle Scholar
  • 29 Lipton RB, Croop R, Stock EG. et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 2019; 381 (02) 142-149
    CrossrefPubMedGoogle Scholar
  • 30 Croop R, Lipton RB, Kudrow D. et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397 (10268): 51-60
    CrossrefPubMedGoogle Scholar
  • 31 Ailani J, Lipton RB, Goadsby PJ. et al; ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med 2021; 385 (08) 695-706
    CrossrefPubMedGoogle Scholar
  • 32 Chiang C-C, VanderPluym JH. Ubrogepant in the acute management of migraine: a narrative review. J Pain Res 2021; 14: 1185-1192
    CrossrefPubMedGoogle Scholar
  • 33 Lipton RB, Dodick D, Goadsby PJ. et al. Efficacy of Ubrogepant in the acute treatment of migraine with mild pain versus moderate or severe pain. Neurology 2022; August 17, 2022 DOI: 10.1212/WNL.0000000000201031.
    CrossrefPubMedGoogle Scholar
  • 34 Dodick DW, Lipton RB, Ailani J. et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache 2020; 60 (04) 686-700
    CrossrefPubMedGoogle Scholar
  • 35 Croop R, Goadsby PJ, Stock DA. et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet Lond Engl 2019; 394 (10200): 737-745
    CrossrefPubMedGoogle Scholar
  • 36 Chiang C, Arca KN, Dunn RB. et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache 2021; 61 (04) 620-627
    CrossrefPubMedGoogle Scholar
  • 37 Berman G, Croop R, Kudrow D. et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache 2020; 60 (08) 1734-1742
    CrossrefPubMedGoogle Scholar
  • 38 Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 2020; 40 (09) 892-902
    CrossrefPubMedGoogle Scholar
  • 39 Zhai L, Sakurai T, Kamiyoshi A. et al. Endogenous calcitonin gene-related peptide suppresses ischemic brain injuries and progression of cognitive decline. J Hypertens 2018; 36 (04) 876-891
    CrossrefPubMedGoogle Scholar
  • 40 Mulder IA, Li M, de Vries T. et al. Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol 2020; 88 (04) 771-784
    CrossrefPubMedGoogle Scholar
  • 41 Chiang C-C, Shahid AH, Harriott AM. et al. Evaluation and treatment of headache associated with moyamoya disease – a narrative review. Cephalalgia 2022; 42 (06) 542-552
    CrossrefPubMedGoogle Scholar
  • 42 Knievel K, Buchanan AS, Lombard L. et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia 2020; 40 (01) 19-27
    CrossrefPubMedGoogle Scholar
  • 43 Eli Lilly and REYVOW™ [package insert] n.d. Accessed September 22, 2022 at: https://doi.org/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
    CrossrefPubMed
  • 44 Nelson DL, Phebus LA, Johnson KW. et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010; 30 (10) 1159-1169
    CrossrefPubMedGoogle Scholar
  • 45 Shapiro RE, Hochstetler HM, Dennehy EB. et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain 2019; 20 (01) 90
    CrossrefPubMedGoogle Scholar
  • 46 Tepper SJ. Medication-overuse headache. Continuum (Minneap Minn) 2012; 18 (04) 807-822
    PubMedGoogle Scholar
  • 47 Chiang C-C, Schwedt TJ, Wang S-J, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia 2016; 36 (04) 371-386
    CrossrefPubMedGoogle Scholar
  • 48 Robbins MS, Victorio MC, Bailey M. et al. Quality improvement in neurology: Headache Quality Measurement Set. Neurology 2020; 95 (19) 866-873
    CrossrefPubMedGoogle Scholar
  • 49 Robbins MS, Victorio MCC, Bailey M. et al. Quality improvement in neurology: Headache Quality Measurement Set. Headache 2021; 61 (01) 219-226
    CrossrefPubMedGoogle Scholar
  • 50 Lipton RB, Mullin K, Lovegren M. et al. Long-term, open-label safety study of rimegepant 75 mg for the treatment of migraine (Study 201): interim analysis of safety and exploratory efficacy (IHC-PO-127). Cephalalgia 2019; 39 (01) 1-337 . Available at https://journals.sagepub.com/doi/10.1177/0333102419859835
    PubMedGoogle Scholar
  • 51 McGinley JS, L'Italien GJ, Thiry A, Coric V, Croop R, Lipton RB. Rimegepant 75 mg results in reductions in monthly migraine days: secondary analysis of a multicenter, open label, long-term safety study of rimegepant for the acute treatment of migraine. Neurology 2020; 94 (Suppl. 15) 1793 . Available at https://n.neurology.org/content/94/15_Supplement/1793
    PubMedGoogle Scholar
  • 52 Schwedt TJ, Hentz JG, Sahai-Srivastava S. et al; MOTS Investigators. Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial. Neurology 2022; 98 (14) e1409-e1421
    CrossrefPubMedGoogle Scholar
  • 53 Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial. Cephalalgia 2019; 39 (01) 3-14
    CrossrefPubMedGoogle Scholar
  • 54 Schoenen J, Vandersmissen B, Jeangette S. et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013; 80 (08) 697-704
    CrossrefPubMedGoogle Scholar
  • 55 Tassorelli C, Grazzi L, de Tommaso M. et al; PRESTO Study Group. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology 2018; 91 (04) e364-e373
    CrossrefPubMedGoogle Scholar
  • 56 Yarnitsky D, Dodick DW, Grosberg BM. et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache 2019; 59 (08) 1240-1252
    CrossrefPubMedGoogle Scholar
  • 57 Rapoport AM, Bonner JH, Lin T. et al. Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. J Headache Pain 2019; 20 (01) 83
    CrossrefPubMedGoogle Scholar
  • 58 Starling AJ, Tepper SJ, Marmura MJ. et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018; 38 (06) 1038-1048
    CrossrefPubMedGoogle Scholar
  • 59 Ltd. N. RELIVION® FDA request n.d. Accessed September 22, 2022 at: https://doi.org/https://www.accessdata.fda.gov/cdrh_docs/pdf20/K203419.pdf
    CrossrefPubMed
  • 60 Hershey AD, Lin T, Gruper Y. et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache 2021; 61 (02) 310-317
    CrossrefPubMedGoogle Scholar
  • 61 Grazzi L, Egeo G, Liebler E, Padovan AM, Barbanti P. Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study. Neurol Sci 2017; 38 (Suppl. 01) 197-199
    CrossrefPubMedGoogle Scholar
  • 62 Irwin SL, Qubty W, Allen IE, Patniyot I, Goadsby PJ, Gelfand AA. Transcranial magnetic stimulation for migraine prevention in adolescents: a pilot open-label study. Headache 2018; 58 (05) 724-731
    CrossrefPubMedGoogle Scholar
  • 63 Clark O, Mahjoub A, Osman N, Surmava A-M, Jan S, Lagman-Bartolome AM. Non-invasive neuromodulation in the acute treatment of migraine: a systematic review and meta-analysis of randomized controlled trials. Neurol Sci 2022; 43 (01) 153-165
    CrossrefPubMedGoogle Scholar
  • 64 Burch R. Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review. Headache 2020; 60 (01) 200-216
    CrossrefPubMedGoogle Scholar
  • 65 Hamilton KT, Halker Singh RB, Ailani J, Butterfield RJ, Robbins MS. Migraine treatment in pregnancy: an American Headache Society survey. Headache 2020; 60 (10) 2594-2596
    CrossrefPubMedGoogle Scholar
  • 66 Hamilton KT. The evidence (or lack thereof) for treatment of primary headache during pregnancy and lactation. Headache 2021; 61 (01) 9-10
    CrossrefPubMedGoogle Scholar
  • 67 Saldanha IJ, Cao W, Bhuma MR. et al. Management of primary headaches during pregnancy, postpartum, and breastfeeding: a systematic review. Headache 2021; 61 (01) 11-43
    CrossrefPubMedGoogle Scholar
  • 68 Ishii R, Schwedt TJ, Kim S-K, Dumkrieger G, Chong CD, Dodick DW. Effect of migraine on pregnancy planning: insights from the American Registry for Migraine Research. Mayo Clin Proc 2020; 95 (10) 2079-2089
    CrossrefPubMedGoogle Scholar
  • 69 Halker Singh RB, Sirven JI. Migraine headaches and family planning: what we think we know. Mayo Clin Proc 2020; 95 (10) 2054-2056
    CrossrefPubMedGoogle Scholar
  • 70 May A, Leone M, Afra J. et al; EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13 (10) 1066-1077
    CrossrefPubMedGoogle Scholar
  • 71 Diener HC, May A. Drug treatment of cluster headache. Drugs 2022; 82 (01) 33-42
    CrossrefPubMedGoogle Scholar
  • 72 Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991; 325 (05) 322-326
    CrossrefPubMedGoogle Scholar
  • 73 van Vliet JA, Bahra A, Martin V. et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003; 60 (04) 630-633
    CrossrefPubMedGoogle Scholar
  • 74 Cittadini E, May A, Straube A, Evers S, Bussone G, Goadsby PJ. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 2006; 63 (11) 1537-1542
    CrossrefPubMedGoogle Scholar
  • 75 Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev 2013; (07) CD008042
    PubMedGoogle Scholar